Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Children's Oncology Group
Fujian Medical University Union Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
M.D. Anderson Cancer Center
University of Washington
National Cancer Institute (NCI)
Guangdong Second Provincial General Hospital
Mayo Clinic
National Cancer Institute (NCI)
Ruijin Hospital
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Fred Hutchinson Cancer Center
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Moleculin Biotech, Inc.
National Cancer Institute (NCI)
First Affiliated Hospital of Zhejiang University
Kura Oncology, Inc.
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Genmab
Regeneron Pharmaceuticals
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Beijing 302 Hospital
Chinese PLA General Hospital
Stichting Hemato-Oncologie voor Volwassenen Nederland
University Hospital, Caen
Daiichi Sankyo
H. Lee Moffitt Cancer Center and Research Institute